Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4079446 | 0.84 | OPRL1 (0.48) | OPRL1OPRM1 | |
| SCHEMBL20866603 | 0.83 | OPRL1 (0.59) | OPRL1OPRM1SLC6A3SLC6A2CHRM2 | |
| SCHEMBL4085368 | 0.82 | OPRL1 (0.42) | OPRL1OPRM1SLC6A2SLC6A4 | |
| SCHEMBL4072298 | 0.80 | OPRM1 (0.52) | OPRL1OPRM1SLC6A2SLC6A4 | |
| SCHEMBL3409128 | 0.79 | OPRM1 (0.67) | OPRL1OPRM1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5168924 | 0.78 | OPRM1 (0.54) | OPRL1OPRM1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4081238 | 0.77 | OPRM1 (0.65) | OPRL1OPRM1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL21766654 | 0.77 | OPRM1 (0.52) | OPRL1OPRM1SLC6A3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL5165622 | 0.77 | OPRM1 (0.52) | OPRL1OPRM1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL249993 | 0.76 | NPC1 (0.43) | OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745010-B1 | SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | claimed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | PKD1, DDC, DPYD | OPRL1 2751/4885OPRM1 3175/4885SLC6A3 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.